ReviewNature reviews. Cancer2023
Advances in PET imaging of cancer.
Review in Nature reviews. Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic significance ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Pooled it
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Application of immunoPET imaging to enhance head and neck squamous cell carcinoma clinical management.Frontiers in oncology · 2025Pooled it
- Whole-mouse immunolabeling at cellular resolution for comprehensive 3D atlases.Nature protocols · 2026Review
- PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.European journal of nuclear medicine and molecular imaging · 2026Article
- Expanding the Medicinal Chemistry Toolbox for PET Imaging: AliphaticChemical & biomedical imaging · 2026Article
- Recent advances in [Nuclear medicine and biology · 2026Review
- Advances in research on layered double hydroxides for biomedical applications.Smart molecules : open access · 2026Review
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- Clinical impact of routine second‑opinion reading of [¹⁸F]FDG‑PET/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network.European journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Dipicolinic acid (DPA)-based chelators for zirconium-89 PET imaging applications.Bioorganic & medicinal chemistry letters · 2026Article
- Potential and challenges of Positron Emission Tomography beyond conventional preclinical and clinical imaging.Zeitschrift fur medizinische Physik · 2026Review
- Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis.European radiology · 2026Article
- Advanced methods in deuterium metabolic imaging.Magma (New York, N.Y.) · 2026Review
- The impact of scan time on dynamic [Formula: see text]-FAPI-04 total-body PET parametric imaging generated by deep learning models.EJNMMI physics · 2026Article
- Fluorinated Amphiphilic Dendrimer to Improve PET Imaging of Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Metal-Organic Framework as Contrast Agents for Magnetic Resonance Imaging.Pharmaceutics · 2026Review
- Generalizable CT-free PET attenuation and scatter correction via few-shot cross domain adaptation.NPJ digital medicine · 2026Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imaging has experienced enormous advancements in the areas of imaging technology, imaging probe and contrast development, and data quality, as well as machine learning-based data analysis. Positron emission tomography (PET) and its combination with computed tomography (CT) or magnetic resonance imaging (MRI) as a multimodality PET-CT or PET-MRI system offer a wealth of molecular, functional and morphological data with a single patient scan. Despite the recent technical advances and the availability of dozens of disease-specific contrast and imaging probes, only a few parameters, such as tumour size or the mean tracer uptake, are used for the evaluation of images in clinical practice. Multiparametric in vivo imaging data not only are highly quantitative but also can provide invaluable information about pathophysiology, receptor expression, metabolism, or morphological and functional features of tumours, such as pH, oxygenation or tissue density, as well as pharmacodynamic properties of drugs, to measure drug response with a contrast agent. It can further quantitatively map and spatially resolve the intertumoural and intratumoural heterogeneity, providing insights into tumour vulnerabilities for target-specific therapeutic interventions. Failure to exploit and integrate the full potential of such powerful imaging data may lead to a lost opportunity in which patients do not receive the best possible care. With the desire to implement personalized medicine in the cancer clinic, the full comprehensive diagnostic power of multiplexed imaging should be utilized.
Indexed as
Identifiers
37258875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.